학술논문
A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
Document Type
Academic Journal
Author
Source
ejHaem. November 2022, Vol. 3 Issue 4, p1445, 4 p.
Subject
Language
English
Abstract
Chronic lymphocytic leukemia (CLL) was projected to cause 4320 deaths in 2021 in the US [1]. Chemo‐immunotherapy regimens are commonly associated with unfavorable adverse events (AEs) [2, 3]. Targeted therapies [...]